Share on StockTwits

Hikma Pharmaceuticals Plc (LON:HIK)‘s stock had its “buy” rating restated by equities researchers at Peel Hunt in a research report issued on Wednesday. They currently have a GBX 1,850 ($30.93) target price on the stock. Peel Hunt’s target price points to a potential upside of 2.61% from the company’s current price.

A number of other firms have also recently commented on HIK. Analysts at Panmure Gordon reiterated a “hold” rating on shares of Hikma Pharmaceuticals Plc in a research note on Tuesday. They now have a GBX 1,580 ($26.41) price target on the stock. Separately, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Hikma Pharmaceuticals Plc in a research note on Thursday, August 14th. They now have a GBX 1,900 ($31.76) price target on the stock. Finally, analysts at Barclays reiterated an “overweight” rating on shares of Hikma Pharmaceuticals Plc in a research note on Thursday, August 14th. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of GBX 1,802.50 ($30.13).

Shares of Hikma Pharmaceuticals Plc (LON:HIK) opened at 1759.00 on Wednesday. Hikma Pharmaceuticals Plc has a one year low of GBX 1004.00 and a one year high of GBX 1835.00. The stock’s 50-day moving average is GBX 1750. and its 200-day moving average is GBX 1599.. The company’s market cap is £3.479 billion.

Hikma Pharmaceuticals PLC is engaged in the development, manufacture and marketing of a range of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms.

Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with Analyst Ratings Network's FREE daily email newsletter.